MUC16 and TP53 family co-regulate tumor-stromal heterogeneity in pancreatic adenocarcinoma

MUC16/CA125 is one of the few oldest cancer biomarkers still used in current clinical practice. As mesothelium is an abundant source of MUC16 and a major contributor to stromal heterogeneity in PDAC, we investigated the regulation of MUC16 in tumor and stromal compartments individually. The trajectories constructed using the single-cell transcriptomes of stromal cells from KPC tumors demonstrated continuity in the trajectory path between MUC16-expressing mesothelial cells and other CAF subsets. Further, the tumor tissues of MUC16 whole-body knockout (KPCM) showed dysregulation in the markers of actomyosin assembly and fibroblast differentiation (iCAF and myCAF), indicating that MUC16 has an extra-tumoral role in controlling CAF differentiation. Although we found mesothelium-derivative stromal cells to be bystanders in normal pancreas, the proportion of these cells was higher in invasive PDAC, particularly in TP53 deficient tumors. Moreover, we also detail the regulation of MUC16, KRAS, and SOX9 by TP53 family members (TP53 and TP63) using multi-omics data from knockout models, PDAC cell lines, and human PDAC tissues.

[1]  Lynette M. Smith,et al.  Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in pancreatic ductal adenocarcinoma , 2022, Oncogene.

[2]  D. Kufe.  Chronic activation of MUC1-C in wound repair promotes progression to cancer stem cells , 2022, Journal of cancer metastasis and treatment.

[3]  H. Ueno,et al.  Mesothelin Expression is Correlated with Chemoresistance in Stage IV Colorectal Cancer , 2021, Annals of Surgical Oncology.

[4]  R. Brekken,et al.  Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer , 2021, bioRxiv.

[5]  Hannah A. Pliner,et al.  A human cell atlas of fetal gene expression , 2020, Science.

[6]  S. Batra,et al.  Acinar transformed ductal cells exhibit differential mucin expression in a tamoxifen-induced pancreatic ductal adenocarcinoma mouse model , 2020, Biology Open.

[7]  G. Daley,et al.  Pancreatic circulating tumor cell profiling identifies LIN28B as a metastasis driver and drug target , 2020, Nature Communications.

[8]  Xiangyin Kong,et al.  ONECUT2 overexpression promotes RAS-driven lung adenocarcinoma progression , 2019, Scientific Reports.

[9]  D. Tuveson,et al.  Squamous trans-differentiation of pancreatic cancer cells promotes stromal inflammation , 2019, bioRxiv.

[10]  Ross A. Hamilton,et al.  The Signaling Pathways Project, an integrated ‘omics knowledgebase for mammalian cellular signaling pathways , 2019, Scientific Data.

[11]  C. Belka,et al.  Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches , 2019, Radiation oncology.

[12]  A. Maitra,et al.  Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution , 2019, bioRxiv.

[13]  A. Rojas,et al.  The Wilms’ tumor suppressor gene regulates pancreas homeostasis and repair , 2019, PLoS genetics.

[14]  D. Tuveson,et al.  TP63-Mediated Enhancer Reprogramming Drives the Squamous Subtype of Pancreatic Ductal Adenocarcinoma , 2018, Cell reports.

[15]  Chun Jimmie Ye,et al.  Lineage dynamics of murine pancreatic development at single-cell resolution , 2018, Nature Communications.

[16]  Paul Hoffman,et al.  Integrating single-cell transcriptomic data across different conditions, technologies, and species , 2018, Nature Biotechnology.

[17]  D. Kufe,et al.  MUC1-C activates polycomb repressive complexes and downregulates tumor suppressor genes in human cancer cells , 2018, Oncogene.

[18]  Steven J. M. Jones,et al.  Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. , 2017, Cancer cell.

[19]  Y. Koyama,et al.  Mesothelin/mucin 16 signaling in activated portal fibroblasts regulates cholestatic liver fibrosis , 2017, The Journal of clinical investigation.

[20]  J. V. van Putten,et al.  Transmembrane Mucins: Signaling Receptors at the Intersection of Inflammation and Cancer , 2017, Journal of Innate Immunity.

[21]  Bo Ram Kim,et al.  SOX2 and PI3K Cooperate to Induce and Stabilize a Squamous-Committed Stem Cell Injury State during Lung Squamous Cell Carcinoma Pathogenesis , 2016, PLoS biology.

[22]  Andrew D. Rouillard,et al.  Enrichr: a comprehensive gene set enrichment analysis web server 2016 update , 2016, Nucleic Acids Res..

[23]  R. Gibbs,et al.  Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.

[24]  Ash A. Alizadeh,et al.  Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.

[25]  A. Regev,et al.  Spatial reconstruction of single-cell gene expression , 2015, Nature Biotechnology.

[26]  M. Stack,et al.  Membrane-type I matrix metalloproteinase-dependent ectodomain shedding of mucin16/ CA-125 on ovarian cancer cells modulates adhesion and invasion of peritoneal mesothelium , 2014, Biological chemistry.

[27]  R. Samant,et al.  Role of osteopontin in the pathophysiology of cancer. , 2014, Matrix biology : journal of the International Society for Matrix Biology.

[28]  I. Gipson,et al.  Comparison of the Transmembrane Mucins MUC1 and MUC16 in Epithelial Barrier Function , 2014, PloS one.

[29]  A. Ashworth,et al.  Genome-wide characterization reveals complex interplay between TP53 and TP63 in response to genotoxic stress , 2014, Nucleic acids research.

[30]  S. Batra,et al.  Emerging role of mucins in epithelial to mesenchymal transition. , 2013, Current cancer drug targets.

[31]  Joshua M. Stuart,et al.  The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.

[32]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[33]  R. Tripaldi,et al.  The Trop-2 signalling network in cancer growth , 2013, Oncogene.

[34]  T. Noda,et al.  Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma , 2012, Cancer science.

[35]  K. Samuel,et al.  Acute Multiple Organ Failure in Adult Mice Deleted for the Developmental Regulator Wt1 , 2011, PLoS genetics.

[36]  C. Rancourt,et al.  Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells , 2011, British Journal of Cancer.

[37]  E. Lundberg,et al.  Towards a knowledge-based Human Protein Atlas , 2010, Nature Biotechnology.

[38]  R. Bast,et al.  MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse. , 2008, Differentiation; research in biological diversity.

[39]  L. Thompson,et al.  Adenosquamous Carcinoma Of The Pancreas: A Clinicopathologic Series Of 25 Cases , 2001, Modern Pathology.

[40]  O. Dapunt,et al.  Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125. , 1996, Gynecologic oncology.

[41]  A. Zee,et al.  The effect of abdominal surgery on the serum concentration of the tumour‐associated antigen CA 125 , 1990, British journal of obstetrics and gynaecology.

[42]  R. Bast,et al.  Reactivity of a monoclonal antibody with human ovarian carcinoma. , 1981, The Journal of clinical investigation.

[43]  OUP accepted manuscript , 2021, Nucleic Acids Research.